Literature DB >> 22376027

Knocking out the dopamine reuptake transporter (DAT) does not change the baseline brain arachidonic acid signal in the mouse.

Epolia Ramadan1, Lisa Chang, Mei Chen, Kaizong Ma, F Scott Hall, George R Uhl, Stanley I Rapoport, Mireille Basselin.   

Abstract

BACKGROUND: Dopamine transporter (DAT) homozygous knockout (DAT(-/-)) mice have a 10-fold higher extracellular (DA) concentration in the caudate-putamen and nucleus accumbens than do wildtype (DAT(+/+)) mice, but show reduced presynaptic DA synthesis and fewer postsynaptic D(2) receptors. One aspect of neurotransmission involves DA binding to postsynaptic D(2)-like receptors coupled to cytosolic phospholipase A(2) (cPLA(2)), which releases the second messenger, arachidonic acid (AA), from synaptic membrane phospholipid. We hypothesized that tonic overactivation of D(2)-like receptors in DAT(-/-) mice due to the excess DA would not increase brain AA signaling, because of compensatory downregulation of postsynaptic DA signaling mechanisms.
METHODS: [1-(14)C]AA was infused intravenously for 3 min in unanesthetized DAT(+/+), heterozygous (DAT(+/-)), and DAT(-/-) mice. AA incorporation coefficients k* and rates J(in), markers of AA metabolism and signaling, were imaged in 83 brain regions using quantitative autoradiography; brain cPLA(2)-IV activity also was measured.
RESULTS: Neither k* nor J(in) for AA in any brain region, or brain cPLA(2)-IV activity, differed significantly among DAT(-/-), DAT(+/-), and DAT(+/+) mice.
CONCLUSIONS: These results differ from reported increases in k* and J(in) for AA, and in brain cPLA(2) expression, in serotonin reuptake transporter (5-HTT) knockout mice, and suggest that postsynaptic dopaminergic neurotransmission mechanisms involving AA are downregulated despite elevated DA in DAT(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22376027      PMCID: PMC3464054          DOI: 10.3109/00207454.2012.665972

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  55 in total

1.  Distribution of cytoplasmic phospholipase A2 in the normal rat brain.

Authors:  W Y Ong; T L Sandhya; L A Horrocks; A A Farooqui
Journal:  J Hirnforsch       Date:  1999

2.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.

Authors:  C Saunders; J V Ferrer; L Shi; J Chen; G Merrill; M E Lamb; L M Leeb-Lundberg; L Carvelli; J A Javitch; A Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions.

Authors:  F S Hall; X F Li; I Sora; F Xu; M Caron; K P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

4.  Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges.

Authors:  Philip Seeman; Teresa Tallerico; Françoise Ko; Catherine Tenn; Shitij Kapur
Journal:  Synapse       Date:  2002-12-15       Impact factor: 2.562

5.  Selective dopamine receptor stimulation differentially affects [3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease.

Authors:  T Hayakawa; M C Chang; S I Rapoport; N M Appel
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

6.  Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI).

Authors:  Ying Qu; Lisa Chang; Justin Klaff; Andrea Balbo; Stanley I Rapoport
Journal:  Neuropsychopharmacology       Date:  2002-06-05       Impact factor: 7.853

7.  Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice.

Authors:  Qian Li; Christine H Wichems; Li Ma; Louis D Van de Kar; Francisca Garcia; Dennis L Murphy
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

8.  Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats.

Authors:  Mireille Basselin; Epolia Ramadan; Miki Igarashi; Lisa Chang; Mei Chen; Andrew D Kraft; G Jean Harry; Stanley I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-28       Impact factor: 6.200

9.  The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice.

Authors:  Alasdair M Barr; Virginia Lehmann-Masten; Martin Paulus; Raul R Gainetdinov; Marc G Caron; Mark A Geyer
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

10.  Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity.

Authors:  Wei-Dong Yao; Raul R Gainetdinov; Margaret I Arbuckle; Tatyana D Sotnikova; Michel Cyr; Jean-Martin Beaulieu; Gonzalo E Torres; Seth G N Grant; Marc G Caron
Journal:  Neuron       Date:  2004-02-19       Impact factor: 17.173

View more
  3 in total

1.  An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice.

Authors:  Meredith A Fox; Micaella G Panessiti; F Scott Hall; George R Uhl; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

2.  Brain Arachidonic Acid Incorporation and Turnover are not Altered in the Flinders Sensitive Line Rat Model of Human Depression.

Authors:  Helene Blanchard; Lisa Chang; Amir H Rezvani; Stanley I Rapoport; Ameer Y Taha
Journal:  Neurochem Res       Date:  2015-09-24       Impact factor: 3.996

3.  Repeated exposure of adult rats to transient oxidative stress induces various long-lasting alterations in cognitive and behavioral functions.

Authors:  Yoshio Iguchi; Sakurako Kosugi; Hiromi Nishikawa; Ziqiao Lin; Yoshio Minabe; Shigenobu Toda
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.